Markets

All economic and financial indicators grew: Consolidated turnover of €1,311.9 million (1,221.3 in H1 2025); EBITDA of €233.2 million (223.7 in H1 2025); EBIT a of €189.7 million (188.4 in…

Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution

DNA Payments has launched DNA Engage, an innovative platform powered by Taployo that helps merchants turn every payment into an opportunity to build customer relationships, drive loyalty, and gain actionable…

VRB-103, a potential once-weekly, selective oral amylin analog, is being evaluated in a Phase 1 study as both a monotherapy and in combination with VRB-101 (oral ecnoglutide), a once-weekly oral…

Strong sales performance with continued margin expansion, while accelerating the integration of new acquisitions

Second-hand platforms and value-focused retailers are disrupting Western Europe’s fashion market, which accounts for nearly one-fifth of online spending

Growing complexity and interconnected risks driving up insurance spend in construction.

Sales increased by 5% at constant FX to €1,258 million, driven by Fluidra’s customer focus and consistent execution Adjusted EBITDA grew by 6% at constant FX to €321 million, supported…

CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’ is an innovative dosing approach for an ADC which is employed to overcome…

SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1)…